Navigation Links
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
Date:5/9/2013

LAWRENCEVILLE, N.J., May 9, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2013 and provided a business update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer.  ThermoDox® is also being evaluated in a Phase II trial for patients with recurrent chest wall breast cancer, The DIGNITY Study.

Following the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the HEAT Study's primary endpoint, the Company conducted a comprehensive analysis of the data from the Study which was reviewed by its key principal investigators as well as liver cancer and clinical data experts.  These emerging findings from the HEAT Study suggest that RFA dwell time had a positive impact on progression free survival (PFS) and overall survival (OS) in patients treated with ThermoDox® plus RFA when compared to the control group.  This analysis was conducted in a sizable patient subgroup.  These findings will be discussed by two of the HEAT Study's lead investigators at scientific sessions of the World Conference on Interventional Oncology on May 16, 2013. Celsion's lead investigators agree that these are interesting findings which should be further pursued.

"With the support of our medical advisors, we have been working diligently to better understand the clinical data and findings from the Phase III HEAT Study.  Concurrently, we have been taking appropriate measures to position C
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
2. Celsion Corporation Provides Business Update
3. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
4. Celsion Corporation Announces $15 Million Registered Direct Offering
5. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Verenium Corporation to Announce First Quarter 2013 Financial Results
8. EMCO High Voltage Corporation to Exhibit at 61st ASMS Conference on Mass Spectrometry and Allied Topics
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
11. Street Named After EMCO High Voltage Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... SAN DIEGO , April 23, 2015  Neurocrine ... the Company will report its first quarter 2015 results ... 2015. Neurocrine will then host a live conference call and ... Company update Thursday morning, April 30, 2015 at 8:00 ... Participants can access the live conference call by dialing ...
(Date:4/23/2015)... Calif. , April 23, 2015  Cryoport, ... advanced cryogenic logistics solutions for the life sciences ... established its cryogenic logistics solutions within the animal ... with Yancey Farms to support the shipment of ... German Sport horse Stallions. Animal ...
(Date:4/23/2015)... Glemser Technologies is ... Enterprise Content Division (ECD) Certified Solution Partner to ... for Life Sciences Solution Suite . The accreditation ... to provide life sciences companies of all sizes ... EMC Documentum Solution Suite offers four modules: Quality ...
(Date:4/23/2015)... April 23, 2015  Propanc Health Group Corporation ... focuses on the development of cancer treatments for ... lead product includes PRP, a patented formulation consisting ... as well as the enzyme amylase designed to ... a combination of anti-cancer agents working in combination ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Glemser Earns Accreditation for Life Sciences Solution Suite 2Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... - Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765 ... million in 2007 - ... myeloma, with launch on track for ... (Nasdaq: MLNM ) today reported 2007 non-GAAP net,income of $86.9 million and ...
... Feb. 7 ADVENTRX Pharmaceuticals,Inc. (Amex: ... data from,the Company,s marketing-enabling bioequivalence clinical study ... presentation at the 2008,American Association for Cancer ... 12 - 16, 2008 in San Diego, ...
... Ability to Prevent HIV from Replicating, GAITHERSBURG, ... company developing gene therapies for HIV and genetic,diseases, ... VRX496, a gene,therapy for the treatment of AIDS, ... Infections (CROI) in Boston, MA., "This appears ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... 4, 2013 /Press Release/ Toxic waste sites with ... of "healthy years of life lost" in individuals living near ... a study by a Mount Sinai researcher published online today ... Kevin Chatham-Stephens, MD, Pediatric Environmental Health Fellow at the Icahn ...
... ON New research indicates that Mexican-Americans born in the ... significantly more likely than Mexican-American immigrants to report that ... physical activities such as walking, climbing stairs, reaching, lifting, ... in this week,s International Journal of Environmental Research ...
... 2, 2013 CDX Diagnostics, Inc ("CDX") and Shared ... patent infringement action against Histologics, LLC, Poplar HealthCare, PLLC ... Avero Diagnostics (collectively, "Defendants") in the United States District ... York . According to court documents, CDX and ...
Cached Biology News:Toxic waste sites cause healthy years of life lost 2Older US-born Mexican-Americans more physically limited than Mexican-American immigrants: Study 2Shared Medical Resources, LLC files suit against Histologics, LLC, Women's Health Laboratories and Avero Diagnostics for Willful Patent Infringement 2
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
...
Biology Products: